The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer

Jill M. Kolesar, Suzanne E. Dahlberg, Sharon Marsh, Howard L. McLeod, David H. Johnson, Steven M. Keller, Joan H. Schiller

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

NAD(P)H:quinone oxidoreductase 1 (NQO1), is a cytosolic flavoenzyme that catalyzes the two-electron reduction of quinones into hydroquinones. A polymorphism (NQO1*2) alters enzymatic activity of NQO1 resulting in diminished NQO1 activity. Malignancies with NQO1*2 may be resistant to radiation and chemotherapy with resulting poorer survival. NQO1 allele was evaluated in subjects enrolled in ECOG 3590, a randomized comparison of radiation (RT) vs radiation and chemotherapy with cisplatin/etoposide (RCT) in patients with completely resected stages II and IIIa NSCLC. Overall survival was estimated using the Kaplan-Meier method and compared via the log-rank test Cox models were used to assess the impact of covariates on outcomes. Among 152 patients with assessable samples, 24 (16%) had NQO1*2. Median follow-up was 139 months. The presence of NQO1*2/*2 was associated with decreased overall survival (OS) (median in the heterozygote/wild-type group 42.3 vs. 33.5 months in the variant group, p=0.04). In a multivariable Cox model, variant NQO1 (HR=1.58, p=0.05), age <60 (HR=0.67, p=0.04), PS 1 (HR=1.47, p=0.05), cardiovascular disease (HR=1.93, p=0.003) and alkaline phosphatase <100 mg/ml (HR=0.59, p=0.005) were all significant predictors of OS. NQO1*2/*2 may be an independent predictor of poor overall survival in individuals with resected stages II and IIIa NSCLC. Although the basis for the NQO1 association with decreased survival requires additional evaluation, NQO1 may represent a biomarker for guiding individualized therapy.

Original languageEnglish (US)
Pages (from-to)1765-1772
Number of pages8
JournalOncology Reports
Volume25
Issue number6
DOIs
StatePublished - Jun 2011

Fingerprint

Non-Small Cell Lung Carcinoma
Survival
Radiation
Proportional Hazards Models
Hydroquinones
Drug Therapy
Quinones
Etoposide
Heterozygote
NAD
Cisplatin
Alkaline Phosphatase
Oxidoreductases
Cardiovascular Diseases
Biomarkers
Alleles
Electrons
Neoplasms

Keywords

  • Lung cancer
  • NAD(P)H
  • p53
  • Polymorphism
  • Quinone oxidoreductase 1

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kolesar, J. M., Dahlberg, S. E., Marsh, S., McLeod, H. L., Johnson, D. H., Keller, S. M., & Schiller, J. H. (2011). The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer. Oncology Reports, 25(6), 1765-1772. https://doi.org/10.3892/or.2011.1249

The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer. / Kolesar, Jill M.; Dahlberg, Suzanne E.; Marsh, Sharon; McLeod, Howard L.; Johnson, David H.; Keller, Steven M.; Schiller, Joan H.

In: Oncology Reports, Vol. 25, No. 6, 06.2011, p. 1765-1772.

Research output: Contribution to journalArticle

Kolesar, Jill M. ; Dahlberg, Suzanne E. ; Marsh, Sharon ; McLeod, Howard L. ; Johnson, David H. ; Keller, Steven M. ; Schiller, Joan H. / The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer. In: Oncology Reports. 2011 ; Vol. 25, No. 6. pp. 1765-1772.
@article{47d5ba764e82479f9d508d591f3bc081,
title = "The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer",
abstract = "NAD(P)H:quinone oxidoreductase 1 (NQO1), is a cytosolic flavoenzyme that catalyzes the two-electron reduction of quinones into hydroquinones. A polymorphism (NQO1*2) alters enzymatic activity of NQO1 resulting in diminished NQO1 activity. Malignancies with NQO1*2 may be resistant to radiation and chemotherapy with resulting poorer survival. NQO1 allele was evaluated in subjects enrolled in ECOG 3590, a randomized comparison of radiation (RT) vs radiation and chemotherapy with cisplatin/etoposide (RCT) in patients with completely resected stages II and IIIa NSCLC. Overall survival was estimated using the Kaplan-Meier method and compared via the log-rank test Cox models were used to assess the impact of covariates on outcomes. Among 152 patients with assessable samples, 24 (16{\%}) had NQO1*2. Median follow-up was 139 months. The presence of NQO1*2/*2 was associated with decreased overall survival (OS) (median in the heterozygote/wild-type group 42.3 vs. 33.5 months in the variant group, p=0.04). In a multivariable Cox model, variant NQO1 (HR=1.58, p=0.05), age <60 (HR=0.67, p=0.04), PS 1 (HR=1.47, p=0.05), cardiovascular disease (HR=1.93, p=0.003) and alkaline phosphatase <100 mg/ml (HR=0.59, p=0.005) were all significant predictors of OS. NQO1*2/*2 may be an independent predictor of poor overall survival in individuals with resected stages II and IIIa NSCLC. Although the basis for the NQO1 association with decreased survival requires additional evaluation, NQO1 may represent a biomarker for guiding individualized therapy.",
keywords = "Lung cancer, NAD(P)H, p53, Polymorphism, Quinone oxidoreductase 1",
author = "Kolesar, {Jill M.} and Dahlberg, {Suzanne E.} and Sharon Marsh and McLeod, {Howard L.} and Johnson, {David H.} and Keller, {Steven M.} and Schiller, {Joan H.}",
year = "2011",
month = "6",
doi = "10.3892/or.2011.1249",
language = "English (US)",
volume = "25",
pages = "1765--1772",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer

AU - Kolesar, Jill M.

AU - Dahlberg, Suzanne E.

AU - Marsh, Sharon

AU - McLeod, Howard L.

AU - Johnson, David H.

AU - Keller, Steven M.

AU - Schiller, Joan H.

PY - 2011/6

Y1 - 2011/6

N2 - NAD(P)H:quinone oxidoreductase 1 (NQO1), is a cytosolic flavoenzyme that catalyzes the two-electron reduction of quinones into hydroquinones. A polymorphism (NQO1*2) alters enzymatic activity of NQO1 resulting in diminished NQO1 activity. Malignancies with NQO1*2 may be resistant to radiation and chemotherapy with resulting poorer survival. NQO1 allele was evaluated in subjects enrolled in ECOG 3590, a randomized comparison of radiation (RT) vs radiation and chemotherapy with cisplatin/etoposide (RCT) in patients with completely resected stages II and IIIa NSCLC. Overall survival was estimated using the Kaplan-Meier method and compared via the log-rank test Cox models were used to assess the impact of covariates on outcomes. Among 152 patients with assessable samples, 24 (16%) had NQO1*2. Median follow-up was 139 months. The presence of NQO1*2/*2 was associated with decreased overall survival (OS) (median in the heterozygote/wild-type group 42.3 vs. 33.5 months in the variant group, p=0.04). In a multivariable Cox model, variant NQO1 (HR=1.58, p=0.05), age <60 (HR=0.67, p=0.04), PS 1 (HR=1.47, p=0.05), cardiovascular disease (HR=1.93, p=0.003) and alkaline phosphatase <100 mg/ml (HR=0.59, p=0.005) were all significant predictors of OS. NQO1*2/*2 may be an independent predictor of poor overall survival in individuals with resected stages II and IIIa NSCLC. Although the basis for the NQO1 association with decreased survival requires additional evaluation, NQO1 may represent a biomarker for guiding individualized therapy.

AB - NAD(P)H:quinone oxidoreductase 1 (NQO1), is a cytosolic flavoenzyme that catalyzes the two-electron reduction of quinones into hydroquinones. A polymorphism (NQO1*2) alters enzymatic activity of NQO1 resulting in diminished NQO1 activity. Malignancies with NQO1*2 may be resistant to radiation and chemotherapy with resulting poorer survival. NQO1 allele was evaluated in subjects enrolled in ECOG 3590, a randomized comparison of radiation (RT) vs radiation and chemotherapy with cisplatin/etoposide (RCT) in patients with completely resected stages II and IIIa NSCLC. Overall survival was estimated using the Kaplan-Meier method and compared via the log-rank test Cox models were used to assess the impact of covariates on outcomes. Among 152 patients with assessable samples, 24 (16%) had NQO1*2. Median follow-up was 139 months. The presence of NQO1*2/*2 was associated with decreased overall survival (OS) (median in the heterozygote/wild-type group 42.3 vs. 33.5 months in the variant group, p=0.04). In a multivariable Cox model, variant NQO1 (HR=1.58, p=0.05), age <60 (HR=0.67, p=0.04), PS 1 (HR=1.47, p=0.05), cardiovascular disease (HR=1.93, p=0.003) and alkaline phosphatase <100 mg/ml (HR=0.59, p=0.005) were all significant predictors of OS. NQO1*2/*2 may be an independent predictor of poor overall survival in individuals with resected stages II and IIIa NSCLC. Although the basis for the NQO1 association with decreased survival requires additional evaluation, NQO1 may represent a biomarker for guiding individualized therapy.

KW - Lung cancer

KW - NAD(P)H

KW - p53

KW - Polymorphism

KW - Quinone oxidoreductase 1

UR - http://www.scopus.com/inward/record.url?scp=79954496050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954496050&partnerID=8YFLogxK

U2 - 10.3892/or.2011.1249

DO - 10.3892/or.2011.1249

M3 - Article

VL - 25

SP - 1765

EP - 1772

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 6

ER -